Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Labeling of human clots in vitro with an active-site mutant of t-PA.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine - 1 Feb 1990

Fry E T, Mack D L, Monge J C, Billadello J J, Sobel B E

Abstract excerpt

Prompt detection of acute thrombosis and its response to treatment with thrombolytic agents generally require angiography. Scintigraphic approaches with labeled antibodies to or components of the coagulation and fibrinolytic systems have been disappointing because of prolonged circulating half-lives of tracers and relatively slow or limited binding to thrombi. Accordingly, we developed and characterized a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to In Vitro Techniques
Share to Iodine Radioisotopes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Serine

Share to Threonine

Share to Thrombosis

Share to Tissue Plasminogen Activator

Source

Identifiers

PMID: 2107282

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Labeling of human clots in vitro with an active-site mutant of t-PA.PMID 2107282Read ↗

Effective lysis of model thrombi by a t-PA mutant (A473S) that is resistant to alpha2-antiplasmin.Semantic proximity Read ↗

Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents.Semantic proximity Read ↗

Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator.Semantic proximity Read ↗

Site-directed mutagenesis in human tissue-plasminogen activator. Distinguishing sites in the amino-terminal region required for full fibrinolytic activity and rapid clearance from the circulation.Semantic proximity Read ↗

Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator.Semantic proximity Read ↗

Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis.Semantic proximity Read ↗

Redesigning t-PA for improved thrombolytic therapy.Semantic proximity Read ↗

Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator.Semantic proximity Read ↗

The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: why they are used and how they are made.Semantic proximity Read ↗

Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism.Semantic proximity Read ↗

Amino acid residues in the P6-P'3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation.Semantic proximity Read ↗

Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.